ITM Isotope Technologies Munich SE announced that post hoc subgroup analyses from its Phase 3 COMPETE trial will be presented at the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, scheduled for October 22-25, 2025 in Austin, Texas. The presentation will highlight the efficacy of 177Lu-edotreotide compared to everolimus in patients with gastroenteropancreatic neuroendocrine tumors.
COMPETE Trial Results Drive Conference Presentation
The oral presentation, titled "Efficacy of 177Lu-edotreotide vs Everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial (post hoc subgroup analyses)," will be delivered by Dr. Jaume Capdevila, study investigator and senior medical oncologist at Vall d'Hebron University Hospital, Barcelona. The session is scheduled for Friday, October 24, 2025, from 3:35 pm to 4:50 pm CDT at the JW Marriott Austin.
The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide (ITM-11), ITM's proprietary synthetic targeted radiotherapeutic investigational agent, against everolimus in patients with inoperable, progressive Grade 1 or Grade 2 gastroenteropancreatic neuroendocrine tumors. The trial successfully met its primary endpoint, with 177Lu-edotreotide demonstrating clinically and statistically significant improvement in progression-free survival compared to everolimus.
Expert Panel to Address Treatment Sequencing
ITM will also host a satellite symposium titled "What's Your Next Move? Sequencing Therapies in GEP-NETs" on Friday, October 24, 2025, from 7:00 am to 8:00 am CDT. The symposium will be moderated by Dr. Namrata Vijayvergia, Section Chief of Gastrointestinal Medical Oncology at Fox Chase Cancer Center.
The expert panel includes Dr. Jaume Capdevila from Vall d'Hebron University Hospital, Dr. Jessica Maxwell from The University of Texas MD Anderson Cancer Center, Dr. Jonathan Strosberg from Moffitt Cancer Center, and Dr. Harshad Kulkarni, Chief Medical Advisor at BAMF Health.
Expanding Radiopharmaceutical Pipeline
Beyond the COMPETE trial, ITM is advancing 177Lu-edotreotide through the COMPOSE study, a Phase 3 trial in patients with well-differentiated, aggressive Grade 2 or Grade 3, SSTR-positive GEP-NET tumors. This expanded development program reflects the company's commitment to addressing various patient populations within the neuroendocrine tumor spectrum.
ITM positions itself as a leading radiopharmaceutical biotech company dedicated to developing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. The company leverages two decades of radiopharmaceutical expertise and maintains a broad precision oncology pipeline that includes multiple Phase 3 studies, combining high-quality radioisotopes with various targeting molecules.
The company's approach aims to provide patients with more effective targeted treatments to improve clinical outcomes and quality of life, addressing the needs of cancer patients, clinicians, and partners through excellence in development, production, and global supply of medical radioisotopes.
